{"symbol":"BMY","fiscalQuarter":"Q2-2026","reportDate":"2026-07-30","reportTime":"BMO","status":"upcoming","company":{"name":"Bristol-Myers Squibb Company","sector":"Health Care","industry":"Pharmaceuticals"},"tier":"free","webUrl":"https://earningsnxt.ai/ticker/BMY/earnings/Q2-2026","estimates":{"consensusEps":1.6628,"consensusRevenue":12443.06,"epsLow":1.55,"epsHigh":1.92,"whisperEps":null,"numAnalysts":null},"preBrief":{"companySnapshot":"Bristol-Myers Squibb Company (BMY) is a leading pharmaceutical company focused on discovering, developing, and delivering innovative medicines for serious diseases. With a market cap of $132 billion, it plays a crucial role in the health care sector, particularly in oncology, immunology, and cardiovascular diseases.","keyMetrics":[{"name":"Earnings Per Share (EPS)","why":"EPS is a key indicator of the company's profitability and is closely watched by investors.","consensus":"$1.66"},{"name":"Revenue","why":"Revenue growth reflects the company's ability to sell its products and is vital for assessing overall business health.","consensus":"$12.4B"}],"lastQuarterRecap":{"summary":"In Q1-2026, Bristol-Myers Squibb reported an EPS of $1.58, exceeding expectations by 9.65%. The stock reacted positively, gaining 5.21% the following day.","promises":["Continued focus on expanding its oncology portfolio.","Commitment to maintaining strong operational efficiency.","Plans to enhance pipeline development for new therapies."]},"wallStreetExpectations":{"summary":"Analysts expect Bristol-Myers Squibb to report solid earnings this quarter, driven by strong demand for its key products. The consensus EPS of $1.66 suggests confidence in the company's ongoing performance.","bullCase":"If the company beats EPS estimates, it could signal strong sales growth and effective cost management, leading to a positive stock reaction.","bearCase":"A miss on EPS or revenue could raise concerns about market competition and pricing pressures, potentially leading to a negative stock response."},"optionsSignal":{"impliedMove":"4.83%","context":"The options market is pricing in a move of about 4.83%, indicating some uncertainty around the earnings report."},"earningsTrackRecord":[{"quarter":"Q1-2026","epsSurprise":"+9.65%","reaction":"+5.21%"},{"quarter":"Q4-2025","epsSurprise":"+9.28%","reaction":"+3.30%"},{"quarter":"Q3-2025","epsSurprise":"+10.14%","reaction":"+7.09%"},{"quarter":"Q2-2025","epsSurprise":"-12.63%","reaction":"-5.81%"},{"quarter":"Q1-2025","epsSurprise":"+19.52%","reaction":"+0.33%"}],"pivotalQuestions":[{"question":"Will EPS exceed the consensus estimate of $1.66?","whyItMatters":"A beat on EPS could reinforce investor confidence and lead to a positive stock reaction."},{"question":"What are the revenue expectations for key products this quarter?","whyItMatters":"Understanding revenue from key products will help assess the company's market position and growth potential."}],"thesisBreakLevels":{"bullTrigger":"An EPS of $1.70 or higher would confirm strong operational performance and investor confidence.","bearTrigger":"An EPS below $1.60 would raise concerns about sales and profitability.","context":"This quarter's performance is critical as it will indicate whether the company can maintain its growth trajectory amid market challenges."},"scenarioPlaybook":{"beatAndRaise":"If Bristol-Myers Squibb beats expectations, history suggests a stock increase of around 4.21%, confirming strong demand for its products.","inLineCautious":"If results are in line with expectations, the stock may experience a muted reaction as investors await further guidance.","miss":"A miss on earnings could lead to a decline of about 5.81%, reflecting investor disappointment and concerns about future performance."},"whatTheStreetIsMissing":{"thesis":"The Street may underestimate the impact of new product launches, which could drive higher-than-expected revenue growth this quarter.","supportingPoints":["Bristol-Myers has a strong track record of exceeding EPS estimates, with an 88% beat rate over the last eight quarters.","Recent trends in oncology treatments suggest increasing demand that may not be fully reflected in current estimates."],"riskToConsensus":"If revenue from key products comes in below $11.9 billion, it could undermine the bullish sentiment."},"whatToListenFor":["Updates on the performance of key oncology drugs.","Any changes in guidance regarding future product launches.","Insights into cost management strategies.","Discussion on competitive pressures in the pharmaceutical market.","Management's outlook on overall market conditions."],"metaDescription":"Bristol-Myers Squibb (BMY) reports Q2 2026 earnings July 30. Analysts expect $1.66 EPS on $12.4B revenue. Here's what to watch."}}